Latus is delighted to announce its partnership with
Cancer Research UK, LifeArc & University of Edinburgh
Latus has refocused its core activity from oncology R&D to identify, promote and facilitate the evaluation of treatments for COVID-19. This not for profit project orchestrated by Latus will assess the effectiveness of the existing drugs, Camostat and Nafamostat, to fight the virus.
Latus established a collaboration with Ono Pharmaceutical and Nichi-Iko Pharmaceutical for drugs provision and secured £1m from LifeArc to support clinical evaluation. Latus will now be supported by Cancer Research UK and the University of Edinburgh to implement the SPIKE-1 and SPIKE-2 trials, respectively.
SPIKE trials are designed to be
Immediate...
-
Because Camostat is an established drug
-
This means it is already cleared as safe to use, dramatically reducing lead times
Scalable...
-
Because Camostat is taken as a tablet: two tablets four times a day for two weeks
-
We have the production capacity to make camostat available for 63 million patients immediately
-
That is sufficient to cover the entire population of the UK
-
Early discussions with manufacturers suggest that production could be significantly scaled up in the short-medium term, as needed
Transformative...
-
Because we are trialling a drug to alleviate the symptoms of Covid-19
-
If successful, we have the potential to be able to manage Covid-19 symptoms just like common flu
Our Story
The science behind coronavirus' invasion of human cells
